Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(1.74) per share which missed the analyst consensus estimate of $(1.40) by 24.55 percent. This is a 79.38 percent decrease over losses of $(0.97) per share from the same period last year.